Extracellular and intracellular productions of lysophosphatidic acids and cyclic phosphatidic acids by lysophospholipase D from exogenously added lysophosphatidylcholines to cultured NRK52E cells

Tsutsumi, Toshihiko; Kawabata, Ken‐ichi; Yamazaki, Naoshi; Tsukigawa, Kenji; Nishi, Hiroyuki; Tokumura, Akira

doi:10.1016/j.bbalip.2023.159349

Cited by 4 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HSA is the most abundant plasma protein in human blood and is a major transporter for delivering lipids, including cPA [115]. However, extracellular cPA is hydrolyzed by phosphodiesterase and phospholipase, which leads to LPA formation [116], and the cleavage of fatty acids by phospholipase may limit the effective half-life of cPA. Among these novel compounds, carba derivatives of cPA, in which the phosphate oxygen is replaced with a methylene group at either the sn-2 or sn-3 position, shows a much more potent inhibitory effect than cPA [107].…”

Section: In Vitro and In Vivo Studies Of Cpa As A Therapy For Oamentioning

confidence: 99%

A Review of Cyclic Phosphatidic Acid and Other Potential Therapeutic Targets for Treating Osteoarthritis

Tsukahara,

Imamura,

Morohoshi

2023

Biomedicines

View full text Add to dashboard Cite

Osteoarthritis (OA), a chronic degenerative joint disease, is the most common form of arthritis. OA occurs when the protective cartilage that cushions the ends of bones gradually breaks down. This leads to the rubbing of bones against each other, resulting in pain and stiffness. Cyclic phosphatidic acid (cPA) shows promise as a treatment for OA. In this article, we review the most recent findings regarding the biological functions of cPA signaling in mammalian systems, specifically in relation to OA. cPA is a naturally occurring phospholipid mediator with unique cyclic phosphate rings at the sn-2 and sn-3 positions in the glycerol backbone. cPA promotes various responses, including cell proliferation, migration, and survival. cPA possesses physiological activities that are distinct from those elicited by lysophosphatidic acid; however, its biochemical origin has rarely been studied. Although there is currently no cure for OA, advances in medical research may lead to new therapies or strategies in the future, and cPA has potential therapeutic applications.

show abstract

Section: In Vitro and In Vivo Studies Of Cpa As A Therapy For Oamentioning

confidence: 99%